#Sweden #Stockholm #Glioblastoma #BioArctic #Mesenkia

BioArctic Partners with Mesenkia for Breakthrough in Glioblastoma Treatment

In a significant step forward for oncology research, BioArctic AB, listed on NASDAQ Stockholm, has announced a strategic collaboration with Mesenkia Therapeutics. This partnership aims to innovate treatment strategies for glioblastoma, one of the deadliest and most treatment-resistant forms of brain cancer. Despite advancements in medicine, glioblastoma remains a formidable challenge, with limited therapeutic options and a grim prognosis for patients.

The Collaboration

On August 19, 2026, both companies signed a research collaboration agreement focused on exploring a novel antibody-based approach to glioblastoma treatment. The collaboration will merge BioArctic's proprietary BrainTransporter™ technology with an innovative antibody developed through Mesenkia’s KITAIbodies® platform. This combined effort is particularly significant because effective delivery of large molecules, such as antibodies, into the brain has long been a major obstacle in treating this aggressive cancer.

Targeting Glioblastoma Stem Cells

Central to this research is the targeting of HVEM, a protein that resides on the surface of certain glioblastoma cells, including tumor stem cells. These cells play a pivotal role in the recurrence of tumors and their resistance to treatment. By focusing on these critical components of the tumor, the partnership endeavors to unlock new therapeutic avenues that could substantially improve patient outcomes.

Responsibilities and Future Steps

Under the terms of the agreement, BioArctic will spearhead the development of this new drug candidate by leveraging its expertise in drug delivery alongside Mesenkia's antibody technology. Following the generation of this candidate, both firms plan to conduct preclinical studies to validate the effectiveness of their combined approaches. The outcomes of these studies will dictate subsequent steps in the research and development process.

Implications for the Future

This collaborative venture is more than just a scientific partnership; it marks an important milestone for BioArctic, as it broadens its pipeline to include oncology alongside its existing focus on neurodegenerative diseases. Gunilla Osswald, CEO of BioArctic, expressed excitement regarding the collaboration, emphasizing the urgent need for new therapeutic options for glioblastoma patients.

“In combining our innovative BrainTransporter technology with Mesenkia’s pioneering antibody approach, we aim to tackle essential disease-driving mechanisms, advancing potential treatments for this devastating cancer,” said Osswald.

Moa Fransson, CEO of Mesenkia, echoed this sentiment, stating that their joint efforts represent a pivotal approach to addressing the significant challenges of delivering effective therapies directly to glioblastoma tumor cells throughout the brain. This strategic collaboration not only aims to improve current treatment paradigms but also aspires towards the long-term goal of enhancing treatment options for patients in dire need.

About Mesenkia Therapeutics

Mesenkia is a pre-clinical biotechnology company that focuses on developing next-generation biological drug candidates tailored for glioblastoma treatment. Its foundations are built on premier research collaborations between Uppsala University and the University of Tokyo, aimed at understanding the mechanisms behind tumor formation. Mesenkia seeks to utilize its advanced KITAIbodies® platform to facilitate the future development of therapeutics across various medical indications through strategic partnerships.

About BioArctic

BioArctic AB is a Swedish research-driven biopharmaceutical company committed to crafting innovative treatments aimed at mitigating the effects of neurodegenerative diseases. Known for creating Leqembi®, the world's first drug proven to slow the progression of early Alzheimer's disease, BioArctic is dedicated to advancing its research endeavors. Beyond Alzheimer’s, the company is engaged in developing therapies targeting Parkinson's disease, ALS, and other neurological conditions using its proprietary BrainTransporter™ technology to improve drug delivery to the brain.

This collaboration between BioArctic and Mesenkia holds promise not just for glioblastoma patients but for the entire field of oncology, showcasing the power of innovative partnerships in combatting complex medical challenges.